Abstract
Hemodialysis (HD) sustains life for more than millions of people worldwide, without which most would die within a few weeks. The life-sustaining treatment depends on an extracorporeal blood device and requires caregivers to in-depth process detailed aspects of dialysis procedure in addition to an understanding of the pathophysiology of the uremic state. Patients with end-stage kidney disease routinely relies on HD to preserve life since half a century ago. Several early pioneers deserve to be remembered for laying the foundation for HD, which had become technically feasible nowadays. The government approval of public funding for HD made the life-sustaining kidney replacement available for virtually all patients. In this chapter, we review the physical, chemical, and clinical principles of HD as they relate closely to the treatment of uremia patients and the complications associated with HD. The descriptions of other replacement therapies, such as transplantation and peritoneal dialysis, are reviewed in the following chapters.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brenner & Rector’s the kidney. Chapter 65. 9th ed. 2012.
Himmelfarb J. Chronic kidney disease, dialysis, and transplantation. Chapter 20. 3rd ed. 2010.
Ahmad S. Manual of clinical dialysis. Chapter 1 and 2. 2nd ed. 2009.
Larry Jameson J. Harrison’s nephrology and acid-base disorders. Chapter 12. 2nd ed. 2013.
Kallenbach JZ. Review of HD for nurses and dialysis personnel. Chapter 18. 9th ed. 2015.
Golper TA, et al. HD: core curriculum 2014. Am J Kidney Dis. 2014;63:153–63.
Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogens is and prevention. Kidney Int. 1994;45:629–35.
So Metz F, Mir S, Tutuncuoglu S. Potential prophylactic use of benzodiazepines for hemodialysis-associated seizures. Pediatr Nephrol. 2000;14:367–9.
Canzanello VJ, Burkart JM. Hemodialysis-associated muscle cramps. Semin Dial. 1992;5:299–304.
Canzanello VJ, Hylander-Rossner B, Sands RE, et al. Comparison of 50% dextrose water, 25% mannitol, and 23.5% saline for the treatment of hemodialysis-associated muscle cramps. ASAIO Trans. 1991;37:649–52.
Cruz DN, Mahnensmith RL, Perazella MA. Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? Am J Kidney Dis. 1997;30(6):772–9.
Daugirdas JT, Ing TS. First use reactions during hemodialysis: a definition of subtypes. Kidney Int. 1988;24:S37–43.
Pezerella M. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis. 2001;38(Suppl 4):S26–36.
Liyanage T, et al. Worldwide access to treatment for end stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kindey Int. 2013; 3(Suppl): 1–150.
National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: HD adequacy 2006, peritoneal dialysis adequacy 2006, and vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S1–322.
Woo K, Lok CE. New insights into dialysis vascular access: what is the optimal vascular access type and timing of access creation in CKD and dialysis patients? Clin J Am Soc Nephrol. 2016;11:1487–94.
Lazrak HH, René É, Elftouh N, Leblanc M, Lafrance JP. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. BMC Nephrol. 2017;18:187.
Santo M, Valentina P, Luigi T, Enrico F. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014;9:2173–88.
Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the HD prescription on patient morbidity. N Engl J Med. 1981;305:1176–81.
Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance HD. N Engl J Med. 2002;347:2010–9.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of HD patients. J Am Soc Nephrol. 2009;20:645–54.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ye, H. et al. (2020). Hemodialysis. In: Yang, J., He, W. (eds) Chronic Kidney Disease. Springer, Singapore. https://doi.org/10.1007/978-981-32-9131-7_17
Download citation
DOI: https://doi.org/10.1007/978-981-32-9131-7_17
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9130-0
Online ISBN: 978-981-32-9131-7
eBook Packages: MedicineMedicine (R0)